Industry: Healthcare

OFF LIST - 761 consecutive market days: OFF LIST as of 05/28/2013 Through 11/14/2016

Resverlogix Corp., a clinical stage biotechnology company, develops small molecule therapeutics for Bromodomain and ExtraTerminal (BET) inhibition. The company is developing apabetalone (RVX-208), a small molecule selective BET domain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, Alzheimer s disease, and orphan diseases. Resverlogix Corp. is headquartered in Calgary, Canada.

Current Quote*
Last: $2.350
Change: -0.063
Book: $54.200
Volume: 16,816

As Of: 08/20 16:16 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol RVXCF

  • No BuyIns.Net Alerts Available for RVXCF

Graphs for RVXCF

3 Month Graph

6 Month Graph

1 Year Graph